Tiger Cub John Griffin’s Blue Ridge Capital Up to 6% of Endo Health Solutions Inc (ENDP)

Blue Ridge Capital, a hedge fund managed by John Griffin, has filed a 13G with the SEC to disclose a position of 6.6 million shares in Endo Health Solutions Inc (NASDAQ:ENDP), a $4.1 billion market cap pharmaceutical company. Griffin had previously worked for legendary investor Julian Robertson at Tiger Management; he and the other hedge fund managers who got their start there are often called “Tiger cubs.” We track quarterly 13F filings from hedge funds and other notable investors as part of our work developing investment strategies (we have found, for example, that the most popular small cap stocks among hedge funds generate an average excess return of 18 percentage points per year) and can also see using our database that Blue Ridge had not owned any shares at the beginning of this year (find Griffin’s favorite stocks).

Endo Health Solutions Inc (NASDAQ:ENDP) has reported its results for the first quarter of 2013. According to the company’s 10-Q, revenue increased by 3% versus a year earlier. With costs of goods sold falling and the business spending less than half as much as it had in Q1 2012 in research and development, operating income came in at over $140 million after adding back a special item related to legal contingencies. Endo Health Solutions Inc (NASDAQ:ENDP) had actually taken an operating loss in the first quarter of last year, so this is a noticeable improvement. Because of an increase in working capital, however, the company used almost $60 million in cash for its operating activities in the quarter; between that, capital expenses, and paying down a term loan its cash balance was reduced to about $340 million.

BLUE RIDGE CAPITALWall Street analysts are expecting $4.50 in earnings per share for this year, placing Endo Health Solutions Inc (NASDAQ:ENDP)’s stock price at a current-year P/E multiple of only 8. The sell-side is projecting EPS to decline in the following year, and as a result the forward earnings multiple is 10. That’s still fairly cheap, but we would be a bit concerned that business would continue to shrink. John Levin’s Levin Capital Strategies initiated a position of 2.8 million shares in Endo Health Solutions Inc (NASDAQ:ENDP) during the fourth quarter of 2012 (see Levin’s stock picks). Billionaire Steve Cohen’s SAC Capital Advisors cut its stake by about 50% between October and December, though it still closed the year with 2.2 million shares in its portfolio (check out more stocks SAC owned).

Other drug companies include Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Gilead Sciences, Inc. (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), and Pfizer Inc. (NYSE:PFE). Teva is the cheapest of these companies in terms of consensus earnings forecasts for 2014, with a forward P/E of only 7. However, that figure assumes a considerable improvement on the bottom line from current conditions despite revenue and earnings being down recently. Pfizer is a somewhat interesting dividend stock, with a yield of 3.3% at current prices; its earnings were up over 50% last quarter compared to the first quarter of 2012, but revenue was actually down 9%. It does look a bit cheap, and so might be worth looking into why its financials are behaving this way. Abbott and Gilead trade between 16 and 18 times forward earnings estimates. Gilead’s trailing P/E is considerably higher as the stock has more than doubled in the last year, but the company has been recording good growth numbers and the market is apparently anticipating further increases in earnings in the future.

As a result it might also be worthwhile to check out what the next few years could look like for Gilead and see if it is in fact an attractive growth stock. We’ve also mentioned Pfizer as being of interest. As for Endo Health Solutions Inc (NASDAQ:ENDP), it’s interesting that Griffin is buying but as we’d mentioned analysts (who are normally bullish) are looking for EPS to decline going forward and so it might be best to wait for another quarter or two of results to see if those are in line with sell-side targets.

Disclosure: I own no shares of any stocks mentioned in this article.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!